What is the 13F Pro Quality Score for DRIO?

13F Pro ranks DarioHealth Corp. (DRIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DRIO's current score at https://13fpro.ai/research/DRIO (free sign-up required for the full ranking).

Where does 13F Pro source DRIO data?

All DarioHealth Corp. fundamentals and ownership data come directly from SEC EDGAR. DarioHealth Corp. files with the SEC under CIK 1533998. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DRIO in?

DarioHealth Corp. (DRIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DRIO research updated on 13F Pro?

DRIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DarioHealth Corp.(DRIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1533998 DRIO stock profile & AI dashboard →

13F Pro Quality Score

18.9/100

Rank #2,702 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

34.5/100

Profitability

5.7/100

Balance Sheet

5.4/100

Earnings Quality

30.0/100

Free Cash Flow

6.3/100

Institutional Flow

50.0/100

Revenue Scale

5.8/100

Dilution Risk

85.6/100

DRIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for DarioHealth Corp. (DRIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DRIO at 18.9/100 on a 32-signal composite quality model, placing it at rank #2,702 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.4) and profitability (5.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), DarioHealth Corp. reports quarterly revenue of $5.6M, net income of $-8.2M, free cash flow of $-6.1M. Top institutional holders of DRIO by reported 13-F value include Nantahala Capital Management,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. DRIO trades on the Nasdaq exchange and files with the SEC under CIK 1533998. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DRIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DarioHealth Corp. directly from SEC EDGAR. DarioHealth Corp.'s 13F Pro composite quality score has ranged between 8 and 28 since 2022, currently 18.9 — an improving long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about DarioHealth Corp.

Quirks, history, and lore behind DRIO — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap digital health company · listed on Nasdaq · headquartered in New York · focused on chronic disease management.
2
The Numbers
Annual revenue in the low tens of millions of dollars — still in growth mode, with the company spending heavily to scale its platform and not yet consistently profitable.
3
The History
Founded in Israel, it later shifted its corporate base to the U.S. while keeping deep R&D roots in Tel Aviv — a classic move for Israeli med-tech startups eyeing American markets.
4
The Secret
Its business model wraps AI-powered software around connected medical devices to help patients manage conditions like diabetes, hypertension, and mental health — all from home.
5
The Lore
The company's platform is designed to be sold through employers and health plans as a benefit, putting it squarely in the crowded but booming digital therapeutics space.
6
The Giveaway
Its name literally sounds like a friendly doctor — because "Dario" is the brand of its flagship smart glucometer that started it all.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$5.6M

Net Income

Q1 2026

$-8.2M

Free Cash Flow

Q1 2026

$-6.1M

D/E Ratio

Q1 2026

0.50

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+9.9% YoY

$22.4MFY 2025

FY21 $20.5MFY22 $27.7MFY23 $20.4MFY25 $22.4M

Net Income

+29.8% YoY

$-41.7MFY 2025

FY21 $-76.8MFY22 $-62.2MFY23 $-59.4MFY25 $-41.7M

Operating Income

+34.8% YoY

$-36.7MFY 2025

FY21 $-76.5MFY22 $-56.8MFY23 $-56.2MFY25 $-36.7M

EPS (Diluted)

+424.4% YoY

$10.12FY 2025

FY21 $4.07FY22 $2.54FY23 $1.93FY25 $10.12

Total Assets

+14.2% YoY

$110.1MFY 2025

FY21 $100.8MFY22 $119.2MFY23 $96.4MFY25 $110.1M

Total Debt

+7.7% YoY

$30.7MFY 2025

FY21 $0.00FY22 $35.8MFY23 $28.5MFY25 $30.7M

Op. Cash Flow

+14.6% YoY

$-25.9MFY 2025

FY21 $-50.4MFY22 $-47.8MFY23 $-30.4MFY25 $-25.9M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018
Revenue	$22.4M +9.9%	$20.4M -26.4%	$27.7M +34.8%	$20.5M +171.4%	$7.6M +2.2%	$7.4M
Net Income	$-41.7M +29.8%	$-59.4M +4.4%	$-62.2M +19.0%	$-76.8M -332.8%	$-17.7M +0.4%	$-17.8M
Operating Income	$-36.7M +34.8%	$-56.2M +1.1%	$-56.8M +25.7%	$-76.5M -332.0%	$-17.7M -0.1%	$-17.7M
EPS (Diluted)	$10.12 +424.4%	$1.93 -24.0%	$2.54 -37.6%	$4.07	—	—
Total Assets	$110.1M +14.2%	$96.4M -19.1%	$119.2M +18.3%	$100.8M +310.2%	$24.6M +74.4%	$14.1M
Total Debt	$30.7M +7.7%	$28.5M -20.2%	$35.8M	$0.00	—	—
Operating Cash Flow	$-25.9M +14.6%	$-30.4M +36.5%	$-47.8M +5.1%	$-50.4M -220.6%	$-15.7M -37.1%	$-11.5M

AI Insight: DRIO Financial Trends

DarioHealth stabilized operating losses and reduced debt in Q1 2026, but revenue remains depressed and company burns cash.

• Operating income loss narrowed to $-7M in Q1 2026 from $-9M in Q4 2025 and $-16M in Q2 2024.

• Total debt fell to $31M in Q1 2026 from peak $36M in Q2 and Q3 2025; equity $62M.

• Revenue contracted to $5M–$6M range in 2025–Q1 2026 versus $6M–$8M in 2024; operating cash burn remains $6M–$7M per quarter.

⚠ Revenue decline and persistent quarterly operating cash burn of $6M–$7M at current burn rate limit runway without new funding.

⚠ Equity volatility: swung from $59M (Q3 2024) to $75M (Q3 2025) to $62M (Q1 2026) signals ongoing losses eroding capital.

AI Insight: DRIO Ratio Trends

Operating margin improved to −130.9% in Q1 2026 from −163.7% in Q4 2025, signaling reduced cash burn, but company remains deeply unprofitable across all return metrics.

• Operating margin contracted from −139.3% (Q1 2025) to −163.7% (Q4 2025), then recovered to −130.9% (Q1 2026)—volatility masks underlying profitability struggle.

• ROIC improved from −55.1% (Q3 2024) to −31.3% (Q1 2026), a 23.8pp swing, driven by lower negative operating income relative to invested capital.

• Leverage (D/E) stable at 0.50 in Q1 2026 vs. 0.42 in Q2 2024; moderate debt load amid persistent losses provides some balance-sheet cushion.

⚠ Company has not achieved positive operating, net, or return margins in any quarter; path to breakeven unclear without revenue acceleration.

⚠ ROE at −52.9% (Q1 2026) shows shareholder value destruction persists; even modest improvement masks continued inability to generate returns.

Get alerted when DRIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DarioHealth Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DRIO

Nantahala Capital Management, LLC
$4.9M610,690 sh
VANGUARD CAPITAL MANAGEMENT LLC
$528.6K65,910 sh
GEODE CAPITAL MANAGEMENT, LLC
$496.5K61,878 sh
VANGUARD FIDUCIARY TRUST CO
$241.2K30,070 sh
CITADEL ADVISORS LLC
$164.1K20,460 sh
BlackRock, Inc.
$150.9K18,818 sh
UBS Group AG
$127.5K15,901 sh
NORTHERN TRUST CORP
$106.2K13,237 sh
Vanguard Global Advisers, LLC
$26.6K3,321 sh
MORGAN STANLEY
$8.0K1,000 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$4.9M	610,690
VANGUARD CAPITAL MANAGEMENT LLC	$528.6K	65,910
GEODE CAPITAL MANAGEMENT, LLC	$496.5K	61,878
VANGUARD FIDUCIARY TRUST CO	$241.2K	30,070
CITADEL ADVISORS LLC	$164.1K	20,460
BlackRock, Inc.	$150.9K	18,818
UBS Group AG	$127.5K	15,901
NORTHERN TRUST CORP	$106.2K	13,237
Vanguard Global Advisers, LLC	$26.6K	3,321
MORGAN STANLEY	$8.0K	1,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DRIO on your watchlist

Track score changes the day DarioHealth Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DRIO a good stock to buy?

13F Pro's AI-powered analysis of DarioHealth Corp. (DRIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DRIO are available on the DRIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DRIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DRIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DarioHealth Corp.'s investment landscape.